7333-51-9

Usage

Chemical Properties

white to beige crystalline powder

Uses

Bromo(cyclohexyl)triphenylphosphorane was used as a reactant for Wittig reactions.

InChI:InChI=1/C24H26P.BrH/c1-5-13-21(14-6-1)25(22-15-7-2-8-16-22,23-17-9-3-10-18-23)24-19-11-4-12-20-24;/h1-3,5-10,13-18,24H,4,11-12,19-20H2;1H/q+1;/p-1

Upstream product

• 108-85-0 1-bromocyclohexane 
• 603-35-0 triphenylphosphine 
• 111-24-0 1,5-dibromo-pentane 
• 19493-09-5 Methylenetriphenylphosphorane 

Downstream Products

• 54676-97-0 cyclohexylidene-((Z)-2-methylene-cyclohexyliden)-ethane 
• 874650-46-1 1-bromo-4-chloro-3-cyclohexylidenemethyl-benzene 
• 1434385-91-7 ((1-(cyclohexylidenemethyl)cyclopropyl)ethynyl)benzene 
• 70525-40-5 2-(cyclohexylidenemethyl)pyridine 
• 30125-24-7 1,1-diphenylmethylenecyclohexane 

Relevant academic research and scientific papers

P2Y12 receptor antagonist for nitrile diphenyl thioacetic acid structure and application of P2Y12 receptor antagonist

The invention relates to the field of medicines associated with cardiovascular diseases, in particular to a P2Y12 receptor antagonist containing a nitrile diphenyl thioacetic acid structure, a preparation method of the P2Y12 receptor antagonist as well as application of the P2Y12 receptor antagonist in preparing a medicine for treating the cardiovascular diseases, in particular to thromboembolic disease. (The formula is shown in the description).

P2Y12 receptor antagonists diphenyl thioacetic acid, preparation method and use thereof (by machine translation)

The present invention relates to cardiovascular diseases associated with the medicine field. Specifically, the invention relates to a diphenyl thioacetic acid structure of the P2Y12 receptor antagonists, its preparation method and thereof in the preparation of the treatment of cardiovascular diseases in particular thromboembolic disease in the application. Wherein R1 Is selected from H, C1 - C6 Alkyl; R2 Is selected from H, C1 - C6 Alkyl, C3 - C8 A cycloalkyl. (by machine translation)

FUROISOQUINOLINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF

A compound having a partial structure represented by Formula: or a salt thereof has an excellent phosphodiesterase (PDE) IV-inhibiting effect, and is useful as a prophylactic or therapeutic agent against inflammatory diseases, for example, bronchial asthma, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, autoimmune disease, diabetes and the like.

Reaction of trithiazyl trichloride with active methylene compounds

Activated allylic compounds react with trithiazyl trichloride, (NSCl)3, to give 1,2,5-thiadiazoles 1 and isothiazoles 2. An allylic 2-substituent normally prevents formation of an aromatic 1,2,5-thiadiazole, and isothiazole formation becomes the major pathway. Simple allylic compounds are not very reactive towards (NSCl)3 but a terminal electron withdrawing group (CO2Et) enhances the reactivity. With unsymmetrical allylic compounds, isothiazole formation is regiospecific placing the more electron withdrawing group adjacent to the ring sulfur. 1,3-Diketones give 3-acyl-1,2,5-thiadiazoles; unsymmetrical 1,3-diketones give these thiadiazoles regiospecifically, explicable by cyclisation of an intermediate onto the more reactive carbonyl group. 1,4-Diketones give 3,4-diacyl-1,2,5-thiadiazoles; thus 1,2-dibenzoyl-ethane,-echene and -ethyne all give 3,4-dibenzoylthiadiazole (40-44%). Many of these trithiazyl trichloride reactions provide attractive one-step routes to 1,2,5-thiadiazoles and isothiazoles.